Suchergebnisse - "Kobayashi, Roger"

1

Evaluating Safety, Tolerability, and Efficacy of Subcutaneous Human Immunoglobulin 16.5% Administered at Modified Dosing Regimens in Patients with Primary Immunodeficiency Diseases – Study Design

von: Melamed, Isaac

2020, in: The journal of allergy and clinical immunology

Wird geladen...
2

Long-Term Safety, Efficacy, and Tolerability of Subcutaneous Human Immunoglobulin 16.5% in Patients with Primary Immunodeficiencies

von: Gupta, Sudhir

2021, in: Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward

Wird geladen...
3

Subcutaneous Immunoglobulin 16.5% (Cutaquig) in Primary Immunodeficiency Disease: Safety, Efficacy, and Patient Satisfaction with Modified Dosing Regimens

von: Gupta, Sudhir

2023, in: Clinical immunology

Wird geladen...
4

Efficacy, Safety, and Pharmacokinetics of a New 10 % Liquid Intravenous Immunoglobulin Containing High Titer Neutralizing Antibody to RSV and Other Respiratory Viruses in Subjects with Primary Immunodeficiency Disease

von: Wasserman, Richard L.

2016, in: Journal of clinical immunology

Wird geladen...
5

Interferon-gamma in a family with X-linked lymphoproliferative syndrome with acute Epstein-Barr virus infection

von: Okano, Motohiko

1989, in: Journal of clinical immunology

Wird geladen...
6

Subcutaneous Immunoglobulin 16.5% (Cutaquig) is Safe and Efficacious at Modified Dosing Regimens in Patients With Primary Immunodeficiency Disease

von: Gupta, Sudhir

2022, in: The journal of allergy and clinical immunology

Wird geladen...
7

Pharmacokinetics of a novel human intravenous immunoglobulin 10% in patients with primary immunodeficiency diseases: Analysis of a phase III, multicentre, prospective, open-label study

von: Melamed, Isaac R.

2018transfer abstract, in: The face of wrongdoing? An expectancy violations perspective on CEO facial characteristics and media coverage of misconducting firms

Wird geladen...
8

Efficacy and Safety of Human Intravenous Immunoglobulin 10% (Panzyga®) in Patients with Primary Immunodeficiency Diseases: a Two-Stage, Multicenter, Prospective, Open-Label Study

von: Borte, Michael

2017, in: Journal of clinical immunology

Wird geladen...
9

Subcutaneous Immunoglobulin 16.5% (Cutaquig®) in Primary Immunodeficiency Disease: Safety, Tolerability, Efficacy, and Patient Experience with Enhanced Infusion Regimens

von: Gupta, Sudhir

2023, in: Journal of clinical immunology

Wird geladen...
10

Pharmacokinetics of RI-002, an Investigational Igiv Preparation

von: Mond, James j.

2015, in: Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward

Wird geladen...

Nicht das Richtige dabei?

Schreiben Sie uns!